Losartan and paclitaxel for resistant ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests if adding losartan, a blood pressure medicine, to the chemotherapy drug paclitaxel can help people with ovarian cancer that has stopped responding to platinum-based treatments. It is for those whose cancer has returned within 6 months of platinum therapy or did not respond at all.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced ovarian, fallopian tube, or primary peritoneal cancer (not the mucinous or low-grade serous types).
- Your cancer has measurable tumors (at least 1 cm on a CT or MRI scan).
- Your cancer did not respond or came back within 6 months of platinum chemotherapy, and you have had 4 or fewer treatments for that resistant cancer.
- You have adequate blood counts, liver and kidney function, and are generally able to carry out daily activities (ECOG score 0-2).
- You are not taking certain blood pressure medicines (ACE inhibitors, ARBs, calcium channel blockers, diuretics) and have no severe allergy to paclitaxel.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding telmisartan (a blood pressure medicine) to standard chemotherapy for people with ovarian cancer that no longer responds to platinum-based drugs. The goal is to see if the combination can help control the cancer better.
This trial tests a new targeted therapy called DT2216 combined with the chemotherapy paclitaxel for people with ovarian cancer that is resistant to platinum chemotherapy. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a new form of paclitaxel (a chemotherapy drug) in a lipid suspension for people with ovarian cancer that no longer responds to platinum-based chemo. The goal is to see if this drug can help shrink or control the cancer.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This phase 3 trial tests a new drug, mocertatug rezetecan, against standard treatments for ovarian cancer that no longer responds to platinum chemo. It's for people who have had 1 to 4 prior therapies and may offer a new option if you haven't tried all standard treatments yet.
This Phase 2 study tests whether ONC201 given with weekly paclitaxel can control platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. It may help by shrinking tumors or slowing growth in people whose cancer has progressed after platinum chemotherapy.
Hear when a new Platinum-resistant Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.